Risks of intravitreous injection: A comprehensive review

Retina

Volumn 24, Issue 5, 2004, Pages 676-698

  Jager, Rama D ^a   Aiello, Lloyd Paul ^a   Patel, Samir C ^b   Cunningham Jr , Emmett T ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OSI PHARMACEUTICALS INC   (United States)

Author keywords

Cataract; Complications; Endophthalmitis; Eye hemorrhage; Hypotony; Injection; Intraocular hemorrhage; Intravitreal; Iritis; Ocular hypertension; Pneumatic retinopexy; Uveitis

Indexed keywords

CIDOFOVIR; FOMIVIRSEN; GANCICLOVIR; HYALURONIDASE; METHOTREXATE; OCTAFLUOROPROPANE; PEGAPTANIB; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE ACETONIDE;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIABETES MELLITUS; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; ENDOPHTHALMITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAVITREAL DRUG ADMINISTRATION; IRITIS; LYMPHOMA; MEDLINE; NONHUMAN; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINITIS; REVIEW; SAFETY; SCLERA BUCKLING PROCEDURE; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

CATARACT; ENDOPHTHALMITIS; EYE DISEASES; EYE HEMORRHAGE; HUMANS; INJECTIONS; IRITIS; OCULAR HYPERTENSION; PHARMACEUTICAL PREPARATIONS; PREVALENCE; RETINAL DETACHMENT; RISK FACTORS; SAFETY; UVEITIS; VITREOUS BODY;

EID: 6344282189     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200410000-00002     Document Type: Review

References (111)

1. Baudouin C, Chassain C, Caujolle C, Gastaud P. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica 1996;210:329-335.
2. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-1355.
3. Hodge WG, Lalonde RG, Sampalis J, Deschênes J. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis 1996;174:393-396.
4. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995;102:533-543.
5. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103:1078-1083.
6. Taskintuna I, Rahhal FM, Arevalo JF, et al. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1997;104:1049-1057.
7. Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997;104:1827-1837.
8. The Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002;133:484-498.
9. The Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002;133:475-483.
10. Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105:1404-1410.
11. Young SH, Morlet N, Heery S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992;157:370-373.
12. Hilton GF, Kelly NE, Salzano TC, et al. Pneumatic retinopexy. A collaborative report of the first 100 cases. Ophthalmology 1987;94:307-314.
13. Sebag J, Tang M. Pneumatic retinopexy using only air. Retina 1993;13:8-12.
14. Tornambe PE, Hilton GF. The Retinal Detachment Study Group. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. Ophthalmology 1989;96:772-784.
15. Hattenbach LO, Klais C, Koch FH, Gümbel HO. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 2001;108:1485-1492.
16. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999;30:427-434.
17. Doft BH, Kelsey SF, Wisniewski SR, the EVS Study Group. Additional procedures after the initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study. Ophthalmology 1998;105:707-716.
18. Liu W, Shum C, Martin DF, et al. Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis. J Infect Dis 2000;182:1234-1238.
19. Smith IL, Taskintuna I, Rahhal FM, et al. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch Ophthalmol 1998;116:178-185.
20. Knox CM, Chandler D, Short GA, Margolis TP. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas. Ophthalmology 1998;105:37-44.
21. Ganatra JB, Chandler D, Santos C, et al. Viral causes of the acute retinal necrosis syndrome. Am J Ophthalmol 2000;129:166-172.
22. Bodaghi B, LeHoang P. Testing ocular fluids in uveitis. Ophthalmol Clin North Am 2002;15:271-279.
23. Grigg ME, Ganatra J, Boothroyd JC, Margolis TP. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis 2001;184:633-639.
24. The Eyetech Study Group. Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
25. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986.
26. Gragoudas ES, for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. A prospective, randomized controlled clinical trial of pegaptanib, an anti-VEGF aptamer, for neovascular age-related macular degeneration. New Engl J Med 2004: in press.
27. Chang TS, Tonnu IQ, Globe DR, Fine J. Longitudinal changes in self-reported visual functioning in AMD patients in a randomized controlled phase I/II trial of Lucentis (ranibizumab; rHuFAV v2). Invest Ophthalmol Vis Sci 2004;45:E-Abstract 3098.
28. Heier J, Sy J, McCluskey E, rhuFab V2 Study Group. RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections. Invest Ophthalmol Vis Sci 2003;44.
29. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390.
30. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
31. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
32. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-468.
33. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-673.
34. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-298.
35. Ohm J. Über die behandlung der netzhautablösung durch operative entleerung der subretinalen flüssigkeit und einspritzung von luft in den glaskörper. Albrecht von Graefes Arch Ophthalmol 1911;79:442-450.
36. Schneider J, Frankel SS. Treatment of late postoperative intraocular infections with intraocular injection of penicillin. Arch Ophthalmol 1947;37:304-307.
37. Rycroft B. Penicillin and the control of deep intraocular infection. Br J Ophthalmol 1945;29:57-87.
38. Rosengren B. 300 cases operated upon for retinal detachment; method and results. Acta Ophthalmol (Copenh) 1952;30:117-122.
39. Cibis PA, Becker B, Okun E, Canaan S. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol 1962;68:590-599.
40. Forster RK, Zachary IG, Cottingham AJ Jr, Norton EWD. Further observations on the diagnosis, cause, and treatment of endophthalmitis. Am J Ophthalmol 1976;81:52-56.
41. Peyman GA, Vastine DW, Raichand M. Experimental aspects and their clinical application. Ophthalmology 1978;85:374-385.
42. Blumenkranz M, Hernandez E, Ophir A, Norton EWD. 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984;91:122-130.
43. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23.
44. Blankenship GW. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol 1991;229:62-65.
45. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-1156.
46. Vitravene® Injection (fomivirsen sodium intravitreal injectable). Approval letter, pages 1-4. Vol 2004. U.S. Food and Drug Administration Web site. Available at: www.fda.gov/cder/foi/nda/98/20961_Vitravene_Approv.pdf. Accessed April 29, 2004.
47. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900-1907.
48. Vitrase® (ovine hyaluronidase for intravitreal injection). NDA 21-414 clinical data, pages 134-135. Vol 2004. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3929B1_01_ISTA-Vitrase.pdf. Accessed September 25, 2003.
49. Peyman GA, Nelsen P, Bennett TO. Intravitreal injection of kanamycin in experimentally induced endophthalmitis. Can J Ophthalmol 1974;9:322-327.
50. Peyman GA, Paque JT, Meisels HI, Bennett TO. Postoperative endophthalmitis: a comparison of methods for treatment and prophylaxis with gentamicin. Ophthalmic Surg 1975;6:45-55.
51. Baum JL. The treatment of bacterial endophthalmitis. Ophthalmology 1978;85:350-356.
52. Barza M, Kane A, Baum J. Oxacillin for bacterial endophthalmitis: subconjunctival, intravenous, both, or neither? Invest Ophthalmol Vis Sci 1980;19:1348-1354.
53. McCuen BW 2nd, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
54. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
55. Vitrase® (hyaluronidase for injection). Approval letter for NDA 21-640, pages 1-2. U.S. Food and Drug Administration Web site. Available at: www.fda.gov/cder/foi/appleletter/2004/21640/ltr.pdf. Accessed May 30, 2004.
56. Hauswirth WW, Li Q, Raisler B, et al. Range of retinal diseases potentially treatable by AAV-vectored gene therapy. Novartis Found Symp 2004;255:179-188.
57. GenVec. PEDF program-a new approach to prevent blindness. Available at: www.genvec.com/products_gene_therapy_pedf.asp. Accessed May 30, 2004.
58. Coco RM, Lopez MI, Pastor JC, Nozal MJ. Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes. J Ocul Pharmacol Ther 1998;14:555-563.
59. Wingard LB Jr, Zuravleff JJ, Doft BH, et al. Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes. Invest Ophthalmol Vis Sci 1989;30:2184-2189.
60. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
61. Stay MS, Xu J, Randolph TW, Barocas VH. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res 2003;20:96-102.
62. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544.
63. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
64. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 2002;86:1066.
65. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
66. Moldow B, Sander B, Larsen M, Lund-Andersen H. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci 1999;40:1770-1775.
67. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000;17:1503-1510.
68. Sebag J. Age-related changes in human vitreous structure. Graefes Arch Clin Exp Ophthalmol 1987;225:89-93.
69. Lund-Andersen H, Sander B. The vitreous. In: Kaufman PL, Alm A, eds. Adler's Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2003:293-316.
70. Vitravene® (fomivirsen sodium intravitreal injectable). Medical Officer's Review of NDA 20-961, pages 37-38. Vol 2004. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/foi/nda/98/ 20961_vitravene_medr.pdf. Accessed September 25, 2003.
71. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
72. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
73. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-1282.
74. Friberg TR, Eller AW. Laser pneumatic retinopexy for repair of recurrent retinal detachment after failed scleral buckle-ten years experience. Ophthalmic Surg Lasers 2001;32:13-18.
75. Friberg TR, Eller AW. Pneumatic repair of primary and secondary retinal detachments using a binocular indirect ophthalmoscope laser delivery system. Ophthalmology 1988;95:187-193.
76. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716.
77. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-974.
78. Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002;33:373-378.
79. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
80. Hassan IJ, MacGowan AP, Cook SD. Endophthalmitis at the Bristol Eye Hospital: an 11-year review of 47 patients. J Hosp Infect 1992;22:271-278.
81. Olson JC, Flynn HW Jr, Forster RK, Culbertson WW. Results in the treatment of postoperative endophthalmitis. Ophthalmology 1983;90:692-699.
82. Puliafito CA, Baker AS, Haaf J, Foster CS. Infectious endophthalmitis. Review of 36 cases. Ophthalmology 1982;89:921-929.
83. Sandvig KU, Dannevig L. Postoperative endophthalmitis: establishment and results of a national registry. J Cataract Refract Surg 2003;29:1273-1280.
84. Shane TS, Martin DF, for the Endopthalmitis-Ganciclovir Implant Study Group. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 2003;136:649-654.
85. Shrader SK, Band JD, Lauter CB, Murphy P. The clinical spectrum of endophthalmitis: incidence, predisposing factors, and features influencing outcome. J Infect Dis 1990;162:115-120.
86. Somani S, Grinbaum A, Slomovic AR. Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can J Ophthalmol 1997;32:303-310.
87. Wong TY, Chee SP. The epidemiology of acute endophthalmitis after cataract surgery in an Asian population. Ophthalmology 2004;111:699-705.
88. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology 1998;105:1004-1010.
89. Semmens JB, Li J, Morlet N, Ng J. Trends in cataract surgery and postoperative endophthalmitis in Western Australia (1980-1998): the Endophthalmitis Population Study of Western Australia. Clin Exp Ophthalmol 2003;31:213-219.
90. Montan PG, Koranyi G, Setterquist HE, et al. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology 1998;105:2171-2177.
91. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv Ophthalmol 1998;43:193-224.
92. Speaker MG, Milch FA, Shah MK, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991;98:639-649.
93. Bannerman TL, Rhoden DL, McAllister SK, et al. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol 1997;115:357-361.
94. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004;24:699-705.
95. Bartz-Schmidt KU, Bermig J, Kirchhof B, et al. Prognostic factors associated with the visual outcome after vitrectomy for endophthalmitis. Graefes Arch Clin Exp Ophthalmol 1996;234(suppl 1):S51-S58.
96. Bohigian GM, Olk RJ. Factors associated with a poor visual result in endophthalmitis. Am J Ophthalmol 1986;101:332-341.
97. Sarrafizadeh R, Hassan TS, Ruby AJ, et al. Incidence of retinal detachment and visual outcome in eyes presenting with posterior vitreous separation and dense fundus-obscuring vitreous hemorrhage. Ophthalmology 2001;108:2273-2278.
98. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997;115:733-737.
99. Robinson MR, Reed G, Csaky KG, et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 2000;130:49-56.
100. Cunningham ET Jr. Uveitis in HIV positive patients (editorial). Br J Ophthalmol 2000;84:233-235.
101. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-483.
102. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
103. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-281.
104. Tornambe PE, Hilton GF, Brinton DA, et al. Pneumatic retinopexy. A two-year follow-up study of the multicenter clinical trial comparing pneumatic retinopexy with scleral buckling. Ophthalmology 1991;98:1115-1123.
105. Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000;11:462-467.
106. Kraushar MF, Nussbaum P, Kisch AL. Anaphylactic reaction to intravitreal cefazolin. Retina 1994;14:187-188.
107. Mo J-S, Streilein JW. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001;31:3806-3815.
108. Dick HB, Augustin AJ, Pakula T, Pfeiffer N. Endotoxins in ophthalmic viscosurgical devices. Eur J Ophthalmol 2003;13:176-184.
109. Peters NT, Iskander NG, Anderson Penno EE, et al. Diffuse lamellar keratitis: isolation of endotoxin and demonstration of the inflammatory potential in a rabbit laser in situ keratomileusis model. J Cataract Refract Surg 2001;27:917-923.
110. Park HS, Kim MS. The inflammatory potential of surgical glove lubricants: Biosorb, Keoflo, calcium carbonate and Hydrocote after intravitreal injection. Korean J Ophthalmol 1997;11:51-59.
111. Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res 1997;16:663-669.